¹Aashish Bharti, ²Amandeep Kaur

¹Research Associate, Viral Research and Diagnostic Laboratory, Govt. Medical College, Amritsar, Punjab, India

²Associate Professor, Department of Microbiology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India

Corresponding Author: Amandeep Kaur

Background:
C-reactive protein is a nonspecific, acute-phase, inflammatory protein, whose expression is increased in response to tissue injury, inflammation and infection. The highest concentrations of CRP are found in an individual having some bacterial infections where CRP level increase up to 1,000-fold. The present study was undertaken to determine the C-reactive protein levels in clinically suspected OPD and IPD patient by Latex agglutination test (LAT).
Material and Methods:
Blood samples were collected from clinically suspected OPD and IPD patients with signs of inflammation in plain vacutainer tubes and received in Serology laboratory of Microbiology Department for CRP testing. All blood samples were screened by Qualitative CRP assay by using commercially available kit. Blood samples that were positive were further tested for CRP titre by semi-quantitative test using same kit (Beacon Diagnostics Pvt Ltd ).
Results:
A total of 450 serum samples were received for CRP testing during a period of six months. Higher CRP levels were obtained in patients with chronic inflammatory diseases (76%) and as compared to patients with acute inflammatory diseases (24%).
Conclusion:
CRP is an inexpensive and easily available serological test helpful in correlating severity and mortality of any disease. Early CRP testing can be a very helpful tool to improve the clinical outcomes of patients and decreased mortality.

C-Reactive protein, chronic inflammatory disease, acute inflammatory disease, semi- quantitative

1) Iwalewa EO, McGaw LJ, Naidoo V, Eloff JN. Inflammation: the foundation of diseases and disorders. A review of phytomedicines of South Afr ican origin used to treat pain and inflammatory conditions. Afr J Biotechnol.2007;6(25):2868- 2885.

2) Ciubotaru J, Potempa LA, Wande RC. Production of modified Creactive protein in U937 -derived macrophages. Exp Biol Med.2005; 230(10):762–70.

3) Mantovani A, Garlanda C, Doni A, Bottazzi B. “Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3”. Journal of Clinical Immunology.2008;28(1):1–13.

4) Henry JB. Clinical Diagnosis and Management by Laboratory Methods, Volume 1, W.B Saunders Company, Philadelphia, PA.1999;60-8.

5) Thavasu, PW. Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J Immunol Methods. 1992;153(1-2):115-24

6) Lindbaek M, Hoiby EA, Lermark G, Steinsholt IM and Hjortdahl P. Clinical symptoms and signs in sore throat patients with large colony variant beta haemolytic streptococci groups C or G versus group A. British Journal of General Practice. 2005;55(517):615-9.

7) Williams JR, Ralph C, Molly E. Harmon, Rufus Burlingame, Terry W. Du Clos. Studies of serum Creactive protein in Systemic lupus erythemato sus. J Rheumatol. 2005;32(3):454-61

8) Shrivastava AK, Singh HV, Raizada A, Singh SK, Pandey A, Singh N, Yadav DS, Sharma H. Inflammatory markers in patients with rheumatoid arthritis. Allergo l Immunopathol. 2013;43(1)81-7

9) Andreeva E and Melbye H. Usefulness of C-reactive protein testing in acute cough/respiratory tract infection: an open cluster- randomized clinical trial with C-reactive protein testing in the intervention group BMC Family Practice 2014;15:80.

10) Liu KT, Lin TJ, and Chan HM. Characteristics of febrile patients with normal white blood cell counts and high Creactive protein levels in an emerge ncy department. Kaohsiung J Med Sci. 2008;24(5):248-253

11) Raja MH, Elshaikh E, Williams L, Ahmed MH. The Value of C-Reactive Protein in Enchancing Diagnosis of Acute Appendicitis. Jcurr Surg.2017;7(1-2):7-10

12) Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H. C-reactive protein asa marker of infection in critically ill patients. Clin Microbio l Infect. 2005;11(2):101-8.

13) Cozlea DL, Farcas DM, Nagy A, Keresztesi AA, Tifrea R, Cozlea L, Carașca DL. The Impact of C- Reactive Protein on Global Cardiovascular Risk on Patients with Coronar y Artery Disease. Current Healt h Sciences Journal. 2013,39(4):225-31.

14) Tabassum R, Mia AR, Reza-Ul-Haq KM, Yesmin M, Faruqui JM. C-reactive Protein Level in Type-2 Diabetic Patients Attending Mymen singh Medical College Hospital, Mymen singh Med J. 2017;26(1):56-60

VOLUME 04 ISSUE 10 OCTOBER 2021